Friday, February 08, 2013 11:07:03 AM
Given that timeline, the Obama administration's goal of reducing health care costs, and the May, 2014 patent expiration, the chances of seeing approval this year are decent. (20 to 30 percent? A WAG of course.)
All this assumes, of course, that MNTA was able to replicate Copaxone, which I believe they have.
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
